ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Inaqovi 35 mg/100 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 35 mg decitabine and 100 mg cedazuridine.

Excipient with known effect

Each film-coated tablet contains 306 mg lactose (as lactose monohydrate).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet).

Red, oval biconvex shaped tablet, 14 mm diameter, plain on one side and debossed with 'H35' on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.

Inaqovi in combination with venetoclax is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.

4.2 Posology and method of administration

Treatment must be initiated and supervised by a physician experienced in the use of anticancer therapies.

Posology

Monotherapy

The recommended dose of Inaqovi is 1 tablet once daily on Days 1 through 5 of each 28-day cycle.

Cycles are to be repeated every 28 days. Treatment is to be continued for a minimum of 4 cycles until disease progression or unacceptable toxicity. A complete or partial response may take longer than 4 cycles.

- Substitution with an intravenous decitabine product within a cycle is not recommended.

- Premedication with standard antiemetic therapy prior to each dose to minimise nausea and vomiting is to be considered (see section 4.4).
- A delay or reduction in the dose per cycle is to be considered for patients who experience haematologic and non-haematologic toxicities (see "Dose adjustments").

In combination with venetoclax

The recommended dose of Inaqovi is 1 tablet once daily on Days 1 through 5 of each 28-day cycle.

Cycles are to be repeated every 28 days. Treatment is recommended to be continued for a minimum of 4 cycles until disease progression or unacceptable toxicity.

- Substitution with an intravenous decitabine product within a cycle is not recommended.
- Premedication with standard antiemetic therapy prior to each dose to minimise nausea and vomiting is to be considered (see section 4.4).
- A delay or reduction in the dose per cycle is to be considered for patients who experience haematologic and non-haematologic toxicities (see "Dose adjustments").
- Patients treated with venetoclax may develop tumour lysis syndrome (TLS). Refer to sections 4.2, 4.4 and 4.8 of the venetoclax summary of product characteristics (SmPC) for additional information.
- Information on dosing of venetoclax is provided in section 4.2 of the venetoclax SmPC.

Missed or vomited dose

- If the patient misses a dose within 12 hours of the time it is usually taken, the patient must take the missed dose as soon as possible and resume the normal daily dosing schedule.
- If the patient misses a dose by 12 or more hours, the patient must wait and take the missed dose the following day at the usual time and then extend the dosing period by one day for every missed dose to complete 5 daily doses for each cycle.
- If the patient vomits following dosing, no additional dose is to be taken that day. The next dose must be taken at the usual time and resume the normal daily dosing, with no extension of the dosing period.

Dose adjustments

Monotherapy

Haematologic adverse reactions

The next cycle must be delayed if absolute neutrophil count (ANC) is less than 1.0×10^9/L and platelets are less than 50×10^9/L in the absence of active disease. Complete blood cell (CBC) counts must be monitored until ANC is 1.0×10^9/L or greater and platelets are 50×10^9/L or greater.

In the absence of active disease:

- If haematological recovery occurs (ANC at least 1.0×10^9/L and platelets at least 50×10^9/L) within 2 weeks of the last treatment cycle, treatment is to be continued at the same dose.
- If haematological recovery does not occur (ANC at least 1.0×10^9/L and platelets at least 50×10^9/L) within 2 weeks of the last treatment cycle:
    - Treatment must be delayed for up to 2 additional weeks AND

- The patient must resume treatment at a reduced dose on Days 1 through 4. Further dose reductions have to be considered in the order listed in Table 1 if myelosuppression persists after a dose reduction.
- Dose has to be maintained or increased in subsequent cycles as clinically indicated.

Patients are to be treated with a minimum of 4 cycles of treatments with active disease.

Table 1: Recommended Inaqovi dose reductions for myelosuppression

Dose reduction	Dose
First	1 tablet once daily on Days 1 through 4
Second	1 tablet once daily on Days 1 through 3
Third	1 tablet once daily on Days 1, 3 and 5

Persistent severe neutropaenia and febrile neutropaenia have to be managed with supportive treatment (see section 4.4).

Non-haematologic adverse reactions

Subsequent treatment cycles must be delayed for the following non-haematologic adverse reactions and resumed at the same or reduced dose upon resolution:

- Serum creatinine 2 mg/dL or greater
- Serum bilirubin 2 times the upper limit of normal (ULN) or greater
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2 times the ULN or greater
- Active or uncontrolled infection

Dose adjustments for all other Grade 3 or higher adverse reactions should follow institutional guidelines.

In combination with venetoclax

Blood cell counts have to be monitored frequently through resolution of cytopenias. Dose modification and interruptions for cytopenias are dependent on remission status. Day 1 of Inaqovi dosing cycles should be matched with that used for venetoclax dosing. For Cycle 1, bone marrow assessment for response may be performed as early as Day 22. In the absence of remission (bone marrow blasts < 5%), Inaqovi dosing schedule should not be delayed.

Haematologic adverse reactions

Complete blood cell counts have to be obtained prior to initiating Inaqovi and before each cycle and have to be monitored until neutrophils and platelet counts have recovered to Grade 1 or 2 (see section 4.4).

- If haematological recovery occurs (ANC at least 1.0×10^9/L and platelets at least 50×10^9/L) within 2 weeks of the last treatment cycle, treatment is to be continued at the same dose.
- If haematological recovery does not occur (ANC at least 1.0×10^9/L and platelets at least 50×10^9/L) within 2 weeks of achieving remission, treatment with Inaqovi must be delayed for up to 2 additional weeks and reduction of the number of days of Inaqovi per cycle is to be considered according to Table 2.

Table 2: Recommended Inaqovi dose reductions for adverse reactions

Dose reduction	Dose
First	1 tablet once daily on Days 1 through 3
Second	1 tablet once daily on Days 1, 3 and 5
Third	1 tablet once daily on Days 1 and 3

Persistent severe neutropaenia and febrile neutropaenia have to be managed with supportive treatment (see section 4.4).

Dose modifications for haematologic adverse reactions associated with venetoclax must follow the instructions in the venetoclax SmPC.

Non-Haematologic Adverse Reactions

For Cycle 3 onwards, dose reductions of Inaqovi for non-haematologic adverse reactions are provided in Table 2.

Dose modifications for non-haematologic adverse reactions associated with venetoclax must follow the instructions in the venetoclax SmPC.

Special populations

Hepatic impairment

Studies in patients with hepatic impairment have not been conducted. The need for dose adjustment in patients with hepatic impairment has not been evaluated. If worsening hepatic function occurs, patients should be carefully monitored (see sections 4.4 and 5.2).

Renal impairment

No adjustment of starting dose is recommended for patients with mild or moderate renal impairment (creatinine clearance [CrCl] $\geq$ 30 mL/min/1.73 m^2). Due to the potential for increased adverse reactions, patients with moderate renal impairment (CrCl 30 to 59 mL/min/1.73 m^2) must be monitored. Inaqovi has not been studied in patients with severe renal impairment (CrCl 15 to 29 mL/min/1.73 m^2) or end stage renal disease (CrCl <15 mL/min/1.73 m^2) (see sections 4.4 and 5.2).

Paediatric population

The safety and efficacy of Inaqovi in the paediatric population (aged less than 18 years) have not been established. No data are available.

Method of administration

Monotherapy and in combination with venetoclax

Inaqovi is for oral use. The tablets must be swallowed whole with water at approximately the same time each day. Food is not to be consumed 2 hours before and 2 hours after taking treatment in order to avoid a risk for lack of efficacy (see section 4.5).

Inaqovi must not be chewed, crushed, or broken in order to avoid skin contact or release of active substance into the air.

Inaqovi is a cytotoxic medicinal product. For proper handling and disposal procedures see section 6.6.

In combination with venetoclax

Inaqovi must not be taken at the same time as venetoclax. Administration of Inaqovi and venetoclax is to be separated by at least 2 hours since venetoclax is to be taken with food. See the venetoclax SmPC for further information.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Breast-feeding (see section 4.6).

4.4 Special warnings and precautions for use

Myelosuppression

Fatal and serious myelosuppression can occur with treatment (see section 4.8).

Complete blood cell counts must be obtained prior to the initiation of treatment, prior to each cycle, and as clinically indicated to monitor response and toxicity. Growth factors and anti-infective therapies must be administered for treatment or prophylaxis as appropriate. The next cycle must be delayed and resumed at the same or reduced dose as recommended (see sections 4.2 and 4.8). Patients must be monitored for signs and symptoms of infection and treated promptly.

Tumour lysis syndrome

For patients taking venetoclax, due to the risk of tumour lysis syndrome (TLS), refer to the venetoclax SmPC sections 4.2, 4.4 and 4.8 for additional information.

Neutropaenia

Supportive treatments include, administration of prophylactic antibiotics and/or growth factor support (e.g., G-CSF) for neutropaenia according to institutional guidelines. For situations where administration must be delayed, see section 4.2.

Respiratory, thoracic and mediastinal disorders

Cases of interstitial lung disease (ILD) (including pulmonary infiltrates, organising pneumonia and pulmonary fibrosis) without signs of infectious aetiology have been reported in patients receiving intravenous decitabine. Patients with an acute onset or unexplained worsening of pulmonary symptoms must be carefully assessed to exclude ILD. If ILD is confirmed, appropriate treatment must be initiated (see section 4.8).

Hepatic impairment

Use in patients with hepatic impairment has not been established. Caution must be exercised in the administration of medicinal product to patients with hepatic impairment and in patients who develop signs or symptoms of hepatic impairment. Liver function tests must be performed prior to the initiation of therapy, prior to each treatment cycle, and as clinically indicated (see sections 4.2 and 5.2).

Renal impairment

Use in patients with severe renal impairment has not been studied. Caution must be exercised in the administration of the medicinal product to patients with severe renal impairment (CrCl < 30 mL/min). Renal function tests must be performed prior to the initiation of therapy, prior to each treatment cycle, and as clinically indicated (see sections 4.2 and 5.2).

Cardiac disease

Patients with a history of severe congestive heart failure or clinically unstable cardiac disease were excluded from clinical studies and therefore, the safety and efficacy of the medicinal product in these patients has not been established. Cases of cardiomyopathy with cardiac decompensation, in some cases reversible after treatment discontinuation, dose reduction or corrective treatment, have been reported in the postmarketing setting with intravenous decitabine (see section 4.8). Patients, especially those with a history of cardiac disease, must be monitored for signs and symptoms of heart failure.

Differentiation syndrome

Cases of differentiation syndrome (also known as retinoic acid syndrome) have been reported during the post-marketing period with intravenous decitabine (see section 4.8). Differentiation syndrome may be fatal (see section 4.8). Treatment with high-dose intravenous corticosteroids and haemodynamic monitoring must be considered at first onset of symptoms or signs suggestive of differentiation syndrome. Treatment must be temporarily discontinued until symptoms resolve, and if resumed, caution is advised.

Administration of antiemetics

Nausea and vomiting may occur during treatment. Administration of standard antiemetic therapy prior to each dose should be considered to minimise nausea and vomiting.

Excipients

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

4.5 Interaction with other medicinal products and other forms of interaction

Effect of other medicinal products on Inaqovi

Decitabine and cedazuridine are not substrates or inhibitors for cytochrome P450 (CYP450); thus interactions with CYP inhibitors or inducers are not expected.

Cytidine deaminase inhibitors

Because decitabine is a substrate for the cytidine deaminase (CDA) enzyme, which metabolises decitabine resulting in an inactive deaminated form, other medicinal products inhibiting CDA should be avoided, as co-administration may result in increased decitabine exposure.

Effect of Inaqovi on other medicinal products

Medicinal products metabolised by cytidine deaminase

Cedazuridine is an inhibitor of CDA and thereby increases the exposure of decitabine following oral administration. Concomitant administration of Inaqovi with medicinal products metabolised by CDA (i.e., cytarabine, gemcitabine, azacitidine) may result in increased systemic exposure with a potential for increased toxicity of these medicinal products. Co-administration of Inaqovi with medicinal products metabolised primarily by CDA should be avoided.

Food

Overall decitabine exposure has been shown to be reduced when decitabine is administered with a high-fat, high-calorie meal or a low fat, low-calorie meal (see section 4.2 and section 5.2).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in men and women

Due to the genotoxic potential of decitabine (see section 5.3), women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Inaqovi and for 6 months following completion of treatment. Men should use effective contraceptive measures and be advised to not father a child while receiving Inaqovi, and for 3 months following completion of treatment (see section 5.3).

The use of decitabine and cedazuridine with hormonal contraceptives has not been studied.

Pregnancy

There are no or a limited amount of human data from the use of decitabine and cedazuridine in pregnant women.

Based on the results of embryo-foetal toxicity studies conducted in animals (see section 5.3), Inaqovi may harm the foetus when administered to pregnant women.

Studies in animals have shown reproductive toxicity (see section 5.3).

Inaqovi is not recommended during pregnancy and in women of childbearing potential not using effective contraception. A pregnancy test should be performed on all women of childbearing potential before treatment is started. If Inaqovi is used during pregnancy, or if a patient becomes pregnant while receiving this medicinal product, the patient should be apprised of the potential hazard to the foetus.

Breast-feeding

It is unknown whether decitabine, cedazuridine, or their metabolites are excreted in breast milk.

A risk to the newborns/infants cannot be excluded.

Inaqovi is contraindicated during breast-feeding (see section 4.3).

Fertility

No human data on the effect of decitabine and cedazuridine on fertility are available. Ovarian and testicular toxicity, including mutagenicity, has been observed in repeat-dose toxicity studies in mice. Because of the possibility of infertility as a consequence of therapy, men should seek advice on conservation of sperm and female patients of childbearing potential should seek consultation regarding oocyte cryopreservation prior to initiating treatment. Before starting treatment or planning pregnancy, consider the above guidance (see section 5.3).

4.7 Effects on ability to drive and use machines

Inaqovi has moderate influence on the ability to drive and use machines. Patients should be advised that they may experience undesirable effects, such as anaemia during treatment. Therefore, caution should be observed when driving a car or operating machinery.

4.8 Undesirable effects

Summary of safety profile

The safety of Inaqovi was evaluated in one Phase 3 study (ASTX727-02-EU) where 80 AML patients received the medicinal product as monotherapy and a Phase 1/2 study (ASTX727-07) where 189 AML patients received Inaqovi in combination with venetoclax. The overall safety profile for Inaqovi is described below and also reflects the known safety profile of intravenous decitabine.

Among the patients who received treatment in ASTX727-02-EU and ASTX727-07 studies, the most common adverse drug reactions (≥ 20%) including Grade ≥ 3 were thrombocytopaenia (ASTX727-02-EU) and febrile neutropenia (ASTX727-07).

The most common serious adverse reactions (≥ 20%) were febrile neutropaenia, sepsis, and pneumonia.

Deaths while on treatment occurred in 24% of patients. The most frequent adverse reactions resulting in death included pneumonia (8%), sepsis (3%) and central nervous system haemorrhage in the setting of thrombocytopaenia (3%).

Tabulated list of adverse reactions

The safety evaluation of adverse reactions is largely based on experience with Dacogen in patients with AML. The safety of Inaqovi in adult patients was evaluated in a safety population that included AML patients from the Phase 3 study (ASTX727-02-EU, N=80) and the phase 1/2 study with Inaqovi in combination with venetoclax (ASTX727-07, N=189).

Table 3 lists adverse drug reactions associated with Inaqovi patients with AML monotherapy (N=80) or combination therapy with venetoclax (N=189), or that have been associated with intravenous decitabine, according to system organ class (SOC) in MedDRA. Within each SOC, the adverse drug reactions are ranked by frequency and then presented in order of decreasing seriousness. The corresponding frequency category for each adverse drug reaction is defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from available data).

Table 3: Adverse drug reactions observed with Inaqovi, Inaqovi combined with venetoclax or with intravenous decitabine therapy in AML patients

MedDRA SOC	MedDRA Term [a]	AML monotherapy (N=80), AML combination therapy (N=189) or IV decitabine	
		All CTCAE Grades Frequency	CTCAE Grade 3-4 Frequency
Infections and infestations	All other infections (viral, bacterial, fungal) [b]	Very common	Very common
	Pneumonia	Very common	Very common
	Sepsis [c]	Very common	Common
	Urinary tract infection [d]	Very common	Common
	Sinusitis (including fungal and bacterial [e])	Common[e]	Common[e]
Blood and lymphatic system disorders	Leukopenia [f]	Very common	Very common
	Thrombocytopaenia [f,g]	Very common	Very common
	Anaemia [f]	Very common	Very common
	Neutropaenia [f]	Very common	Very common
	Febrile neutropaenia	Very common	Very common
	Pancytopaenia [h]	Uncommon [h]	Uncommon [h]
Neoplasms benign, malignant and unspecified (including cysts and polyps)	Differentiation syndrome [i]	Not known	Not known
Metabolism and nutrition disorders	Hyperglycaemia [f]	Very common	Common
Nervous system disorders	Headache	Common	Common
Cardiac disorders	Cardiomyopathy [j]	Uncommon[j]	Uncommon[j]
Respiratory, thoracic and mediastinal disorders	Epistaxis	Common	Common
	Interstitial lung disease	Not known	Not known
Gastrointestinal disorders	Stomatitis [k]	Very common	Common
	Nausea	Very common	Uncommon
	Diarrhoea [l]	Very common	Common[l]
	Vomiting [l]	Very common	Common[l]
	Neutropaenic colitis [m]	Common	Common
Hepatobiliary disorders	Aspartate aminotransferase increased [f]	Very common	Common

MedDRA SOC	MedDRA Term [a]	AML monotherapy (N=80), AML combination therapy (N=189) or IV decitabine	
		All CTCAE Grades Frequency	**CTCAE Grade 3-4 Frequency**
	Alanine aminotransferase increased [f]	Very common	Common
	Alkaline phosphatase increased [f]	Very common	Common
	Bilirubin increased [f]	Very common	Uncommon
Skin and subcutaneous tissue disorders	Acute febrile neutrophilic dermatosis (Sweet's syndrome) [n]	Uncommon [n]	Not applicable [o]
General disorders and administration site conditions	Pyrexia	Very common	Common

[a] The corresponding frequency category for each adverse drug reaction is based on the CIOMS III convention
[b] The most commonly observed include anal abscess, anorectal infection, bacteraemia, cellulitis, herpes virus infection, candidiasis, skin infection, varicella zoster virus infection
[c] The most commonly observed include sepsis, septic shock, systemic candidiasis, urosepsis
[d] The most commonly observed include bacteriuria, cystitis, urinary tract infection
[e] Sinusitis bacterial was not observed in the clinical trial with Inaqovi, however sinusitis (organism not specified) was observed in clinical trials with IV decitabine at a frequency of common
[f] Based on laboratory values
[g] Thrombocytopaenia may lead to bleeding and haemorrhagic reactions that may be fatal
[h] Pancytopaenia, including fatal events, was not observed in the clinical trial with Inaqovi, however it was observed in clinical trials with IV decitabine at a frequency of uncommon
[i] Differentiation syndrome and interstitial lung disease were not observed in the clinical trial with Inaqovi, however they were observed in post-market setting with the use of IV decitabine
[j] Cardiomyopathy was not observed in the clinical trial with Inaqovi, however it was observed in clinical trials with IV decitabine at a frequency of uncommon
[k] The most commonly observed include aphthous ulcer, glossitis, stomatitis, tongue ulceration
[l] Diarrhoea and vomiting, Grade 3-4, were not observed in the clinical trial with Inaqovi, however they were observed in clinical trials with IV decitabine at a frequency of common
[m] Caecitis (including fatal events) was not observed in the clinical trial with Inaqovi, however they were observed in post-market setting with the use of IV decitabine
[n] Acute febrile neutrophilic dermatosis was not observed in the clinical trial with Inaqovi, however it was observed in clinical trials with IV decitabine (all Grades) at a frequency of uncommon
[o] Not applicable (Grade 3-4): Adverse drug reaction has not been observed with either Inaqovi or IV decitabine in both clinical trials and post-market

CTCAE= Common Terminology Criteria for Adverse Events

Description of selected adverse reactions

Haematologic adverse drug reactions

The most commonly reported haematologic adverse drug reactions associated with treatment included leukopaenia, thrombocytopaenia, anaemia, neutropaenia and febrile neutropaenia. These adverse drug reactions are manifestations of myelosuppression and may present as pancytopenia.

Serious bleeding-related adverse drug reactions, such as gastrointestinal haemorrhage and cerebral haemorrhage in the context of severe thrombocytopaenia, were reported in patients receiving treatment. Bleeding may also occur with the eyes, skin, and mucous membranes (mouth and anorectal).

Haematological adverse drug reactions must be managed by routine monitoring of CBCs and early administration of supportive treatments as required. Supportive treatments include administration of prophylactic antibiotics and/or growth factor support (e.g., G-CSF) for neutropaenia and transfusions for anaemia or thrombocytopaenia according to institutional guidelines. For situations where treatment must be delayed, see section 4.2.

Infections and infestations adverse drug reactions

Serious infection-related adverse drug reactions, with potentially fatal outcome, such as septic shock, sepsis, pneumonia, and other infections (viral, bacterial and fungal) were reported in patients receiving treatment.

Gastrointestinal disorders

Occurrences of enterocolitis, including neutropaenic colitis, have been reported during treatment. Enterocolitis may lead to septic complications and may be associated with fatal outcome.

Respiratory, thoracic and mediastinal disorders

Cases of interstitial lung disease (including pulmonary infiltrates, organising pneumonia and pulmonary fibrosis) without signs of infectious aetiology have been reported in patients receiving intravenous decitabine.

Differentiation syndrome

Cases of differentiation syndrome (also known as retinoic acid syndrome) have been reported in patients receiving intravenous decitabine. Differentiation syndrome may be fatal and symptoms and clinical findings include respiratory distress, pulmonary infiltrates, fever, rash, pulmonary oedema, peripheral oedema, rapid weight gain, pleural effusions, pericardial effusions, hypotension and renal dysfunction. Differentiation syndrome may occur with or without concomitant leucocytosis. Capillary leak syndrome and coagulopathy can also occur (see section 4.4).

Other special populations

Elderly

Of the patients in clinical Phase 3 and Phase 1/2 studies who received Inaqovi, 39 % and 28 % were younger than 75 years, and 61 % and 72 % were 75 years and older. No overall differences in safety or effectiveness were observed between patients aged 75 years and older and younger patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Signs and symptoms

Overdose could cause increased myelosuppression and neutropaenia-related infections such as pneumonia and sepsis.

Management

There is no known antidote for overdose with the medicinal product. In the event of an overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, antimetabolites, pyrimidine analogues; cytidine deaminase inhibitor; ATC code: L01BC58.

Mechanism of action

Decitabine is a nucleoside metabolic inhibitor that is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation and/or apoptosis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA.

Cytidine deaminase (CDA) is an enzyme that is responsible for the degradation of cytidine nucleosides, including the cytidine analog decitabine. High levels of CDA in the gastrointestinal tract and liver rapidly degrade these nucleosides and prohibit or limit their oral bioavailability. Cedazuridine inhibits CDA. Oral administration of cedazuridine with decitabine increases the systemic exposure of decitabine via inhibition of first pass metabolism of decitabine in the gut and liver by CDA.

Clinical efficacy and safety

Monotherapy

Inaqovi was evaluated in a Phase 3 (ASTX727-02-EU, NCT03306264) open-label, randomised, 2-cycle, 2-sequence crossover study that included adult patients with *de novo* or secondary AML as defined by World Health Organisation (WHO) criteria, who were not candidates for standard induction chemotherapy. A total of 89 patients were randomised 1:1 to receive Inaqovi (35 mg decitabine and 100 mg cedazuridine) orally in Cycle 1 and decitabine (20 mg/m^2) intravenously in Cycle 2 (n=44) or the reverse sequence (n=45). Both Inaqovi and intravenous decitabine were administered once daily on Days 1 through 5 of the 28-day cycle. Starting with Cycle 3, all patients received Inaqovi orally once daily on Days 1 through 5 of each 28-day cycle until disease progression, death, or unacceptable toxicity. Two of the patients randomised did not receive any study treatment and fifteen were treated in Cycle 1 alone: 8 with Inaqovi, and 7 with intravenous decitabine.

The median treatment duration was 5 months (range 0 to 18 months).

Demographic and baseline disease characteristics are shown in Table 4.

Table 4: Demographic and disease baseline characteristics (Phase 3)

Characteristic	Phase 3 Inaqovi (N=89)
Age (years)	
Median (min, max)	78 (61, 92)
Gender (%)	
Male	54 (60.7)
Female	35 (39.3)
ECOG Performance Score (%)	
0	36 (40.4)
1	53 (59.6)
Disease Category (%)	
de novo AML	57 (64.0)
Secondary AML	32 (36.0)
MDS	18 (20.2)
Other antecedent haematological disorder	7 (7.9)
Therapy-related AML	7 (7.9)
Prior HMA Therapy (%)	
Prior azacitidine	2 (2.2)
Transfusion Dependence[a] (%)	
RBC transfusion dependence	37 (41.6)
Platelet transfusion dependence	14 (15.7)

[a] Defined as documentation of ≥ 2 units of transfusion within 56 days of the first day of study treatment.
AML=acute myeloid leukaemia; ECOG=Eastern Cooperative Oncology Group; HMA=hypomethylating agent; MDS=myelodysplastic syndrome; RBC=red blood cell.

The primary outcome measure of the Phase 3 study was 5-day cumulative decitabine AUC between Inaqovi and intravenous decitabine. Inaqovi achieved $AUC_{0\text{-}24h}$ exposures equivalent to intravenous infusion of decitabine at 20 mg/m^2 (see section 5.2).

Secondary efficacy endpoints included complete response (CR) and the rate of conversion from transfusion dependence to transfusion independence. Descriptive summaries of efficacy are shown in Table 5.

Table 5: Efficacy results in patients with AML study ASTX727-02-EU AML (Phase 3)

Efficacy endpoints	Inaqovi (N=89)
Complete response (%) [95% CI]	21 [13.4, 31.3]
Median duration of CR* - months [95% CI]	5.8 [3.3, NE]
Median time to CR - months [range]	3.0 [1.8, 7.4]
Overall response† (%) [95% CI]	32 [22.0, 42.2]

* From start of CR until relapse or death
† OR included patients with a best response of CR, CRi, and PR
CI=confidence interval; CR=complete response; NE=not evaluable; OR=overall response; PR=partial response.

A patient was considered transfusion independent if the patient was both RBC and platelet transfusion free post-treatment for ≥ 56 consecutive days. Among a total of 41 patients (out of the 87 treated patients) who were dependent on either RBC and/or platelet transfusions at baseline, 14 (34%) became independent of RBC or platelet transfusions during any 56-day post-baseline period. Of the 46 patients who were independent of both RBC and platelet transfusions at baseline, 12 (26%) remained transfusion-independent during any 56-day post-baseline period.

In combination with venetoclax

Inaqovi in combination with venetoclax was evaluated in Study ASTX727-07 Phase 2 Part B, a single-arm, open-label, interventional study that included 101 treated adult patients with newly diagnosed AML who were age 75 years or older, or had comorbidities that precluded the use of intensive induction chemotherapy based on at least one of the following criteria: baseline ECOG performance status of 2-3, severe cardiac disorder or pulmonary comorbidity disorder, moderate hepatic impairment, CLcr ≥30 mL/min to <45 mL/min, or other comorbidity.

Patients received Inaqovi orally once daily on Days 1 through 5 of each cycle and venetoclax once daily as follows: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Days 3 through 28, and 400 mg on Cycles ≥ 2 Days 1 through 28 in each 28-day cycle until disease progression or unacceptable toxicity occurred.

Bone marrow evaluations were, with minimal exceptions, performed within a 7-day window prior to and including Day 1 of a treatment cycle to determine response to treatment and guide decisions on study treatment dosing. For those patients determined to be in remission, dose delay and/or dose reduction were allowed in the case of Grade 4 neutropenia or thrombocytopenia, as well as for Grade 3 or 4 non-haematologic toxicities.

The baseline demographic and disease characteristics are shown in Table 6.

Table 6: Demographics and baseline disease characteristics for Study ASTX727-07 Part B

Characteristic	**INAQOVI+VEN N=101**
Age (years)	
Median (min, max)	78 (63, 88)
Gender (%)	
Male	60
Female	40
ECOG Performance Score (%)	
0-1	78
2	19
3	3
Diagnosis, n (%)	
AML with recurrent genetic abnormalities	14 (13.9)
AML with myelodysplasia-related changes	57 (56.4)
AML, therapy-related	7 (6.9)
AML, not otherwise specified	23 (22.8)

Primary endpoint in Phase 2 Part B was CR as evaluated by investigator. The median follow-up time was 11.2 months (range: 0.3 to 17.5 months). The median treatment duration for Inaqovi was 5.5 months (range: 0.2 to 17.2 months) and the median treatment duration for venetoclax was 5.5 months (range: 0.2 to 17.2 months).

The efficacy results are shown in Table 7.

Table 7: Efficacy results in patients with AML (Study ASTX727-07 Part B)

Efficacy endpoints	**INAQOVI+VEN (N=101)**	
Response rate CR, n (%) (95% CI)*	47 (46.5) (36.5, 56.7)	
Duration of response†‡ Median DoR (CR) (months) (95% CI)	NR (NR, NR)	
Time to response by investigators (all responders) Time to response (months) Median Min, Max	**CR (n=47)** 2.37 0.7, 15.3	

Abbreviations: CI = confidence interval; CR = complete response; DoR = duration of response; NR = not reached
CR was assessed based on 2017 European LeukemiaNet (ELN) criteria (Döhner et al 2017)
* Estimated using Clopper-Pearson method
† Defined as the time from the first of CR until disease progression or death due to any cause, whichever occurred first
‡ Estimated using Kaplan-Meier method

Paediatric population

The obligation to submit the results of studies with Inaqovi in one or more subsets of the paediatric population in AML has been deferred by the European Medicines Agency. See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

The pharmacokinetic (PK) parameters of decitabine and cedazuridine were studied following administration of Inaqovi at the recommended dose in patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia (CMML), and AML.

Decitabine AUC exposures equivalent to those achieved with intravenous infusion of decitabine at 20 mg/m^2 was achieved with the recommended dose of Inaqovi for 5 consecutive days. The geometric mean ratio (GMR) of 5-day total decitabine AUC_{0-24h} between Inaqovi and intravenous decitabine was 99% for patients with MDS/CMML and 100% for patients with AML (90% confidence interval [CI] 93%, 106% and 91%, 109% for MDS/CMML and AML, respectively).

At steady state (achieved with the second dose), circulating plasma concentrations were typically 1.8 times and 1.1 times the Day 1 plasma concentrations for decitabine and cedazuridine, respectively.

In the MDS population (highest number of subjects available; data from AML were similar), decitabine mean (% coefficient of variation [CV]) AUC_{0-24h} exposure at steady state was 189 (55%) ng×h/mL and C_{max} was 145 (55%) ng/mL, respectively. Cedazuridine mean AUC_{0-24h} exposure at steady state (Day 2) was 3290 (45%) ng×h/mL and C_{max} was 349 (49%) ng/mL.

Decitabine exposures when Inaqovi was coadministered with venetoclax (Study ASTX727-07) were comparable to Inaqovi monotherapy.

Absorption

After oral administration of Inaqovi, the median time to peak concentration (t_{max}) at steady state was 3 hours (range: 0.5 to 7.9) for cedazuridine and 1 hour (range: 0.3 to 3) for decitabine. Co-administered with cedazuridine increased decitabine oral relative bioavailability to achieve systemic AUC exposures seen with intravenous decitabine. The bioavailability of cedazuridine was 20.7% (range: 12.7% to 25.6%).

Cedazuridine systemic exposure was not significantly affected by food. High calorie/high fat meals reduced decitabine AUC_{0-24} by 50% and C_{max} by 70%; low calorie/low fat meals reduced AUC_{0-24} by 40% and C_{max} by 45%. Therefore, Inaqovi should be administered in the fasted state, on an empty stomach with no food intake 2 hours before and following administration of the Inaqovi tablet (see section 4.2).

Distribution

Decitabine

Decitabine is approximately 5% bound to human plasma proteins *in vitro*. The geometric mean (CV%) of apparent volume of distribution at steady state is 417 L (54%).

Cedazuridine

Cedazuridine is approximately 35% bound to human plasma proteins *in vitro*. The geometric mean (CV%) of apparent volume of distribution for cedazuridine is 296 L (51%).

Biotransformation

Decitabine

Decitabine is metabolised primarily via deamination by cytidine deaminases and also physiochemical degradation at physiological conditions.

Cedazuridine

The primary metabolic pathway for cedazuridine is conversion to its epimer by physiochemical conversion in GI tract preabsorption.

Elimination

Decitabine

Following a single oral dose of Inaqovi, the mean (CV%) terminal elimination half-life ($t_{1/2}$) of decitabine was 1.2 (23%) hours. The apparent oral clearance (CL/F) was 197 L/h at steady state. The main pathway of elimination for decitabine is metabolic/degradation. Metabolites and degradation products are excreted mainly renally.

Cedazuridine

Following a single oral dose of Inaqovi, the mean (CV%) $t_{1/2}$ of cedazuridine was 6.3 (18%) hours. The mean (CV%) apparent oral clearance (CL/F) was 25.6 (159%) L/h at steady state.

The two major elimination pathways of cedazuridine are renal elimination as parent drug and conversion to its epimer (which is then renally excreted). Following a single oral dose of 100 mg radiolabeled

cedazuridine, 46% (17.1% unchanged) of the administered dose was recovered in urine and 51% was recovered in the faeces.

Linearity/non-linearity
An approximately dose-proportional increase in peak concentrations (C_{max}) and AUC over the dosing interval was observed for decitabine over a dose range from 20 mg to 40 mg in combination with 100 mg cedazuridine.

Exposure for cedazuridine over the dose range evaluated from 40 mg to 100 mg once daily were dose proportional.

Special populations

Age, sex, body weight, and body surface area did not have a clinically relevant effect on the PK parameters of decitabine or cedazuridine after dosing with Inaqovi.

Renal impairment

The PK of decitabine and cedazuridine have not been formally studied in patients with impaired renal function. Patients with normal renal function (N=65) as well as mild (N=129) and moderate (N=103) renal impairment were included in the clinical studies. Renal impairment increases the exposure of cedazuridine (as renal elimination of parent drug is a major elimination pathway) and potentially also increases the exposure of decitabine (due to inhibition of decitabine metabolism caused by increased cedazuridine exposure). Decitabine is mainly metabolised and not excreted renally as unchanged drug. Only three patients with severe renal impairment and no patient with end stage renal disease were included in the studies. See also sections 4.2 and 4.4.

Hepatic impairment

The PK of decitabine and cedazuridine have not been formally studied in patients with hepatic impairment. Very few patients with impaired liver function were included in the clinical studies. Large effects of hepatic impairment on decitabine or cedazuridine exposure are not expected as cedazuridine is not hepatically metabolised and decitabine is metabolised by cytidine deaminase, which is present in several tissues.

5.3 Preclinical safety data

Carcinogenicity, mutagenesis, and impairment of fertility

Carcinogenicity studies with decitabine, cedazuridine, or their combination have not been conducted.

Decitabine was mutagenic in *in vitro* and *in vivo* studies. Decitabine increased mutation frequency in L5178Y mouse lymphoma cells and mutations were produced in an *Escherichia coli* lac-I transgene in colonic DNA of decitabine-treated mice. Decitabine caused chromosomal rearrangements in larvae of fruit flies.

Cedazuridine was mutagenic in the reverse bacterial mutation assay (Ames assay) and was genotoxic in the *in vitro* chromosomal aberration study using human lymphocytes. Cedazuridine was negative for the genotoxicity assessment in three *in vivo* studies including the mouse micronucleus, Comet assay, and the Pig-A assay.

Fertility and repeat-dose toxicity studies in animals showed adverse outcomes on reproductive function and fertility.

In male mice given intraperitoneal injections of 0.15, 0.3, or 0.45 mg/m^2 decitabine (approximately 0.3% to 1% the recommended clinical dose) 3 times a week for 7 weeks, testes weights were reduced, abnormal histology was observed, and significant decreases in sperm number were found at doses ≥ 0.3 mg/m^2. In females mated to males dosed with ≥ 0.3 mg/m^2 decitabine, pregnancy rate was reduced, and preimplantation loss was significantly increased.

Decitabine was administered orally to male rats at 0.75, 2.5, or 7.5 mg/kg/day in cycles of 5-days-on/23-days-off for a total of 90 days. Low testes and epididymis weights, abnormal histology, and reduced sperm number were observed at doses ≥ 0.75 mg/kg (approximately ≥ 3 times the exposure in patients at the recommended clinical dose based on AUC).

Cedazuridine was administered orally to male and female mice at 100, 300, or 1,000 mg/kg/day in cycles of 7-days-on/21-days-off for a total of 91 days. Adverse reactions including abnormal histology in the testes, epididymis, and ovaries, as well as reduced sperm numbers were observed at the 1,000 mg/kg dose (approximately 108 times the exposure in patients at the recommended clinical dose). These findings showed evidence of reversibility following 3 weeks off-dose.

Teratogenic effects

Evidence from the literature indicates that decitabine has carcinogenic potential. The available data from *in vitro* and *in vivo* studies provide sufficient evidence that decitabine has genotoxic potential. Data from the literature also indicate that decitabine has adverse effects on all aspects of the reproductive cycle, including fertility, embryo-foetal development and post-natal development. Multi-cycle repeat-dose toxicity studies in rats and rabbits indicated that the primary toxicity was myelosuppression, including effects on bone marrow, which was reversible on cessation of treatment. Gastrointestinal toxicity was also observed and in males, testicular atrophy that did not reverse over the scheduled recovery periods.

Decitabine administration to neonatal/juvenile rats showed a comparable general toxicity profile as in older rats. Neurobehavioural development and reproductive capacity were unaffected when neonatal/juvenile rats were treated at dose levels inducing myelosuppression.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core

Lactose monohydrate
Hypromellose (E464)
Croscarmellose sodium (E466)
Silica, colloidal anhydrous
Magnesium stearate (E572)

Film-coating

Polyvinyl alcohol (E1203)
Titanium dioxide (E171)
Polyethylene glycol (E1521)
Talc (E553b)

Iron oxide red (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

5 years.

6.4 Special precautions for storage

Store in the original package in order to protect from moisture.
This medicinal product does not require any special temperature storage conditions.

6.5 Nature and contents of container

5 film-coated tablets in PVC/Aluminium blisters (3-ply cold formable aluminium-plastic).

6.6 Special precautions for disposal and other handling

Safe handling of Inaqovi film-coated tablets

The handling of Inaqovi film-coated tablets should follow guidelines for the handling of cytotoxic medicinal products according to prevailing local recommendation and/or regulations.

Provided the outer coating of the tablet is intact, there is no risk in handling Inaqovi film-coated tablets.

Inaqovi film-coated tablets must not be crushed or divided.

Disposal

Any unused medicinal product should be destroyed in accordance with relevant local requirements concerning the disposal of cytotoxic medicinal products.

7. MARKETING AUTHORISATION HOLDER

Otsuka Pharmaceutical Netherlands B.V.
Herikerbergweg 292
1101 CT Amsterdam
Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1756/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 15 September 2023

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu

ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Skyepharma Production S.A.S.
Zone Industrielle Chesnes Ouest
55 Rue Du Montmurier
38070 Saint-Quentin-Fallavier
France

BSP Pharmaceuticals S.p.A.
Via Appia Km. 65,561
04013 Latina Scalo (LT)
Italy

R-PHARM Germany GmbH
Heinrich-Mack-Straße 35
89257 lllertissen
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Inaqovi 35 mg/100 mg film-coated tablets
decitabine/cedazuridine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 35 mg decitabine and 100 mg cedazuridine.

3. LIST OF EXCIPIENTS

Contains lactose. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
5 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.
Swallow tablets whole. Do not chew, crush or break tablets.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Cytotoxic.

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Otsuka Pharmaceutical Netherlands B.V.
Herikerbergweg 292
1101 CT Amsterdam
Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1756/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Inaqovi 35 mg/100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTERS

1. NAME OF THE MEDICINAL PRODUCT

Inaqovi 35 mg/100 mg tablets
decitabine/cedazuridine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Otsuka

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

Inaqovi 35 mg/100 mg film-coated tablets
decitabine/cedazuridine

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Inaqovi is and what it is used for

What Inaqovi is
Inaqovi is a cancer medicine. It contains the active substances decitabine and cedazuridine.

What Inaqovi is used for
Inaqovi is used alone or in combination with another medicine containing the active substance venetoclax to treat acute myeloid leukaemia (AML) in adults, when chemotherapy is not considered suitable. You will be given Inaqovi when you are first diagnosed with AML.

AML is a type of cancer affecting white blood cells called myeloid cells. In AML, myeloid cells multiply and grow very quickly in bone marrow and blood.

How Inaqovi works
Inaqovi contains two active substances that work in different ways. Decitabine works by stopping cancer cells from growing. It also kills cancer cells. Cedazuridine does not affect the cancer cells directly, but it inhibits the break down of decitabine. This increases the amount of decitabine that is available in the body, and so helps to increase the effects of decitabine.

2. What you need to know before you take Inaqovi

Do not take Inaqovi
- if you are allergic to decitabine or cedazuridine, or any of the other ingredients of this medicine (listed in section 6).
- If you are breast-feeding (see section 2, Breast-feeding).

Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Inaqovi if you:
- have lung problems
- have liver problems
- have kidney problems
- have heart problems

Myelosuppression and 'differentiation syndrome'
Inaqovi can cause serious myelosuppression (a condition in which the bone marrow cannot make enough blood cells), or a serious immune reaction called 'differentiation syndrome'. Both may be fatal.
Seek urgent medical attention if you notice any signs and symptoms (for symptoms see section 4).

Tumour Lysis Syndrome
For patients taking Inaqovi in combination with venetoclax, there is a risk of tumour lysis syndrome (TLS). Please refer to the package leaflet of your venetoclax medicinal product for additional information.

Cardiovascular disease
Talk to your doctor if you have a history of heart problems so that you can be monitored for signs and symptoms of heart failure.

Blood tests
You will have blood tests while on treatment. These will occur before you start treatment with Inaqovi, at the start of each treatment cycle or if you notice any signs and symptoms of myelosuppression. These tests are to check that:
- you have enough blood cells, and
- your liver and kidneys are working properly

Your doctor may change or delay your dose of Inaqovi. Your doctor may also give you medicines to help prevent infections.

Children and adolescents
Children and adolescents under 18 years of age must not be given Inaqovi. This medicine has not been studied in this age group.

Other medicines and Inaqovi
Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines before you begin treatment with Inaqovi. Inaqovi may affect the way some medicines work, especially if you are also taking the following medicines to treat:
- cancer, such as cytarabine, gemcitabine or azacitidine

Pregnancy, contraception, breast-feeding and fertility

Pregnancy
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

You should not take Inaqovi during pregnancy as it may harm your unborn baby. If you are able to become pregnant, a pregnancy test is recommended before starting treatment with Inaqovi.

Contraception
Women who are able to become pregnant must use effective contraception both during treatment with Inaqovi, and for 6 months after taking the last dose of Inaqovi.

Men with female partners who are able to become pregnant must use effective contraception both during treatment with Inaqovi, and for 3 months after the last dose.

Talk to your doctor about the most effective methods of contraception.

Breast-feeding
Do not breast-feed during treatment with Inaqovi. This is because it is not known if Inaqovi passes into breast milk and whether this could harm your baby.

Male and female fertility
Inaqovi may affect fertility. It is not known if the effect on fertility is permanent. Talk with your doctor before taking this medicine if you have any concerns, or if you wish to conserve your sperm or freeze your eggs before starting treatment.

Driving and using machines
Inaqovi may affect your ability to drive or use tools or machines. If you feel tired or dizzy after taking Inaqovi, do not drive or use tools or machinery until you feel better.

Inaqovi contains lactose and sodium
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially "sodium-free".

3. How to take Inaqovi

You will be prescribed this medicine by a doctor experienced in the use of anti-cancer medicines. Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

The recommended dose is 1 tablet once a day for the first 5 days of a treatment cycle. This is followed by 23 days without taking this medicine. One treatment cycle has 28 days.

- Swallow your tablets whole, with water, at approximately the same time each day.
- Do not chew, crush, or break your tablets to avoid skin contact or powdered medicine in the air.
- Since taking Inaqovi with food can decrease the effectiveness of the medicine, Inaqovi must be taken without food. Take Inaqovi 2 hours before or 2 hours after a meal.
- If you are taking both Inaqovi and venetoclax as your treatment for AML, do not take them at the same time, since venetoclax is to be taken with food. For venetoclax, please follow the instructions on the venetoclax package leaflet.

You will usually take Inaqovi for at least 4 cycles. Your doctor will do regular blood tests to check on how well you respond to the treatment. Your doctor may delay your dose and change the total number of cycles, depending on how you respond to the treatment.

If you vomit
If you vomit after taking a dose, do not take an additional dose that day. Take the next dose at the usual time the following day.

Your doctor may prescribe you additional medicine to take before each Inaqovi dose to avoid you feeling sick or having to vomit during the treatment.

If you take more Inaqovi than you should
Overdose can result in myelosuppression, sepsis or pneumonia (see section 4, Possible side effects). If you take more Inaqovi than you should, seek **urgent medical attention**.

If you forget to take Inaqovi
If you miss a dose within 12 hours of the time you usually need to take it, you should take the missed dose as soon as possible and resume the normal daily dosing schedule.

If you miss a dose by 12 or more hours: Do no take a dose and take the next dose the following day at the usual time. Extend the dosing period by one day for every missed dose. Please ensure that you complete a total of 5 daily doses for each cycle.

If you stop taking Inaqovi
If you stop taking this medicine your cancer may no longer be controlled, and your symptoms from the cancer may reoccur. Therefore, you should only stop taking this medicine if your doctor tells you to.
If you have any further questions on how to take this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor, pharmacist, or nurse immediately if you notice any of the following serious side effects:
- **fever**: this may be a sign of an infection caused by low levels of white blood cells (**very common** - may affect more than 1 in 10 people).
- **chest pain or shortness of breath (with or without fever or cough)**: these may be signs of pneumonia (**very common**- may affect more than 1 in 10 people) or inflamed lungs (interstitial lung disease (frequency not known).
- **bleeding, including blood in the stools or nose bleed or bruising more easily**: this may be a sign of low blood cells (platelets and red blood cells) (**common** - may affect up to 1 in 10 people).
- **difficulty moving, speaking, understanding or seeing; sudden severe headache, seizure, numbness or weakness in any part of the body**: these may be signs of bleeding inside your head (**common** - may affect up to 1 in 10 people).
- **feeling dizzy or faint, confusion or disorientation, weakness, breathlessness, decreased urination, diarrhoea, feeling sick/vomiting, fever, shivering or feeling very cold, clammy skin or sweating, or cough**: these may be signs and symptoms of an infection of the blood (sepsis) (**very common** - may affect more than 1 in 10 people).
- **fever, cough, difficulty breathing, rash, decreased urine, hypotension (low blood pressure), swelling of the arms or legs and rapid weight gain:** these may be signs of a serious immune reaction (differentiation syndrome) (frequency not known).

Other side effects:

Very common (may affect more than 1 in 10 people)
- urinary tract infection
- infection caused by bacteria, viruses or fungi

- high blood glucose levels
- mouth or tongue ulcers because of painful inflammation of the lining of the mouth
- diarrhoea
- feeling sick and vomiting
- altered liver function tests (increased ALT, AST, alkaline phosphatase, bilirubin)

Common (may affect up to 1 in 10 people)
- inflammation of the sinuses
- headache
- inflamed gut (neutropaenic colitis)

Uncommon (may affect up to 1 in 100 people)
- a drop in the number of red blood cells, white blood cells and platelets
- sudden fever with, multiple red or bluish-red raised painful patches on the skin, usually on the arms, legs, trunk, face or neck. ('Acute Febrile Neutrophilic Dermatosis' or 'Sweet's Syndrome')
- heart muscle disease

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Inaqovi

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister strip after EXP. The expiry date refers to the last day of that month.

Store in the original package in order to protect from moisture.
This medicine does not require any special temperature storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Inaqovi contains
- The active substances are decitabine and cedazuridine. Each film-coated tablet contains 35 mg decitabine and 100 mg cedazuridine.
- The other ingredients are:
  Inaqovi contains lactose and sodium, see section 2.
  Tablet core
  lactose monohydrate, hypromellose (E464), croscarmellose sodium (E466), silica, colloidal anhydrous, magnesium stearate (E572).
  Film-coating
  polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), iron oxide red (E172).

What Inaqovi looks like and contents of the pack
Inaqovi are red, oval biconvex shaped film-coated tablets, 14 mm diameter, plain on one side and debossed with 'H35' on the other side.

They are supplied in foil blister packs containing 5 tablets.

Marketing Authorisation Holder
Otsuka Pharmaceutical Netherlands B.V.
Herikerbergweg 292
1101 CT Amsterdam
Netherlands

Manufacturer
Skyepharma Production S.A.S.
Zone Industrielle Chesnes Ouest
55 Rue Du Montmurier
38070 Saint-Quentin-Fallavier
France

BSP Pharmaceuticals S.p.A.
Via Appia Km. 65,561
04013 Latina Scalo (LT)
Italy

R-PHARM Germany GmbH
Heinrich-Mack-Straße 35
89257 lllertissen
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

België/Belgique/Belgien
Otsuka Pharma Scandinavia AB
Tel: +46 (0) 8 545 286 60

България
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Česká republika
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Danmark
Otsuka Pharma Scandinavia AB
Tlf: +46 (0) 8 545 286 60

Deutschland
Otsuka Pharma GmbH
Tel: +49 (0) 69 1700 860

Lietuva
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Luxembourg/Luxemburg
Otsuka Pharma Scandinavia AB
Tel: +46 (0) 8 545 286 60

Magyarország
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Malta
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Nederland
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Eesti
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Ελλάδα
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

España
Otsuka Pharmaceutical, S.A.
Tel: +34 93 550 01 00

France
Otsuka Pharmaceutical France SAS
Tél: +33 (0)1 47 08 00 00

Hrvatska
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Ireland
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Ísland
Vistor
Sími: +354 (0) 535 7000

Italia
Otsuka Pharmaceutical Italy S.r.l.
Tel: +39 (0) 2 0063 2710

Κύπρος
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Latvija
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Norge
Otsuka Pharma Scandinavia AB
Tlf: +46 (0) 8 545 286 60

Österreich
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Polska
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Portugal
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

România
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Slovenija
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Slovenská republika
Otsuka Pharmaceutical Netherlands B.V.
Tel: +31 (0) 20 85 46 555

Suomi/Finland
Otsuka Pharma Scandinavia AB
Tlf: +46 (0) 8 545 286 60

Sverige
Otsuka Pharma Scandinavia AB
Tlf: +46 (0) 8 545 286 60

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu/en. There are also links to other websites about rare diseases and treatments.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.

ANNEX IV

CONCLUSIONS ON THE REQUEST FOR ONE-YEAR MARKETING PROTECTION PRESENTED BY THE EUROPEAN MEDICINES AGENCY

Conclusions presented by the European Medicines Agency on:

- **one-year marketing protection**

The CHMP reviewed the data submitted by the marketing authorisation holder, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies as further explained in the European Public Assessment Report.